{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:28:25Z","timestamp":1791559705760,"version":"4.3.4"},"reference-count":128,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82130092"],"award-info":[{"award-number":["82130092"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Tumor immunotherapy, as the focus of scientific research and clinical tumor treatment in recent years, has received extensive attention. Due to its remarkable curative effect and fewer side effects than traditional treatments, it has significant clinical benefits for the treatment of various advanced cancers and can improve cancer patient survival in the long term. Currently, most patients cannot benefit from immunotherapy, and some patients may experience tumor recurrence and drug resistance even if they achieve remission overcome. Numerous studies have shown that the abnormal angiogenesis state of tumors can lead to immunosuppressive tumor microenvironment, which affects the efficacy of immunotherapy. Actually, to improve the efficacy of immunotherapy, the application of anti-angiogenesis drugs to normalize abnormal tumor vessel has been widely confirmed in basic and clinical research. This review not only discusses the risk factors, mechanisms, and effects of abnormal and normalized tumor angiogenesis state on the immune environment, but summarizes the latest progress of immunotherapy combined with anti-angiogenic therapy. We hope this review provides an applied reference for anti-angiogenesis drugs and synergistic immunotherapy therapy.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1198972","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T08:03:24Z","timestamp":1685693004000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":52,"title":["The application and research progress of anti-angiogenesis therapy in tumor immunotherapy"],"prefix":"10.3389","volume":"14","author":[{"given":"Jingyao","family":"Tu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunya","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongbiao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianglin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s13046-019-1266-0","article-title":"Advances in cancer immunotherapy 2019 - latest trends","volume":"38","author":"Kruger","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005543","article-title":"Anti-TGF-beta\/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer","volume":"10","author":"Yi","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy","volume":"124","author":"Raskov","year":"2021","journal-title":"Br J Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13045-022-01363-8","article-title":"Combination of oral STING agonist MSA-2 and anti-TGF-beta\/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors","volume":"15","author":"Yi","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-019-0779-5","article-title":"Immune checkpoint inhibitors of PD-L1 as cancer therapeutics","volume":"12","author":"Akinleye","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.03.016","article-title":"Efficacy and safety of first-line immunotherapy combinations for advanced NSCLC: a systematic review and network meta-analysis","volume":"16","author":"Liu","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.5367","article-title":"Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis","volume":"6","author":"Duan","year":"2020","journal-title":"JAMA Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0864-3","article-title":"Biomarkers for predicting efficacy of PD-1\/PD-L1 inhibitors","volume":"17","author":"Yi","year":"2018","journal-title":"Mol Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.06.001","article-title":"Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors","volume":"44","author":"Pitt","year":"2016","journal-title":"Immunity"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment","volume":"18","author":"Yi","year":"2019","journal-title":"Mol Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-017-9562-9","article-title":"Tumor angiogenesis and vascular normalization: alternative therapeutic targets","volume":"20","author":"Viallard","year":"2017","journal-title":"Angiogenesis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/35025220","article-title":"Angiogenesis in cancer and other diseases","volume":"407","author":"Carmeliet","year":"2000","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nature04483","article-title":"Angiogenesis as a therapeutic target","volume":"438","author":"Ferrara","year":"2005","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10456-017-9552-y","article-title":"Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy","volume":"20","author":"Ramjiawan","year":"2017","journal-title":"Angiogenesis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-014-0443-y","article-title":"Resistance to antiangiogenic therapy","volume":"14","author":"Weathers","year":"2014","journal-title":"Curr Neurol Neurosci Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.devcel.2016.03.015","article-title":"The complexity of translating anti-angiogenesis therapy from basic science to the clinic","volume":"37","author":"Ye","year":"2016","journal-title":"Dev Cell"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell"},{"key":"B23","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10456-017-9541-1","article-title":"The role of vasculature in bone development, regeneration and proper systemic functioning","volume":"20","author":"Filipowska","year":"2017","journal-title":"Angiogenesis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10456-013-9341-1","article-title":"Naturally derived factors and their role in the promotion of angiogenesis for the healing of chronic wounds","volume":"16","author":"Morgan","year":"2013","journal-title":"Angiogenesis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10144","article-title":"Molecular mechanisms and clinical applications of angiogenesis","volume":"473","author":"Carmeliet","year":"2011","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/s0065-230x(08)60058-5","article-title":"Tumor angiogenesis","volume":"19","author":"Folkman","year":"1974","journal-title":"Adv Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00423-007-0150-0","article-title":"Angiogenesis in cancer: molecular mechanisms, clinical impact","volume":"392","author":"Eichhorn","year":"2007","journal-title":"Langenbecks Arch Surg"},{"key":"B28","article-title":"Fractals and cancer","volume":"60","author":"Baish","year":"2000","journal-title":"Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9440(10)65006-7","article-title":"Openings between defective endothelial cells explain tumor vessel leakiness","volume":"156","author":"Hashizume","year":"2000","journal-title":"Am J Pathol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9440(10)63540-7","article-title":"Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors","volume":"163","author":"Baluk","year":"2003","journal-title":"Am J Pathol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/bf00437472","article-title":"Leukocyte-endothelial adhesion and angiogenesis in tumors","volume":"15","author":"Jain","year":"1996","journal-title":"Cancer Metastasis Rev"},{"key":"B32","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/s0002-9440(10)64920-6","article-title":"Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors","volume":"160","author":"Morikawa","year":"2002","journal-title":"Am J Pathol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1215\/s1152851705000232","article-title":"The role of pericytes in blood-vessel formation and maintenance","volume":"7","author":"Bergers","year":"2005","journal-title":"Neuro Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.51","article-title":"Microenvironmental regulation of tumour angiogenesis","volume":"17","author":"De Palma","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2174\/138955709788922610","article-title":"HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms","volume":"9","author":"Mar\u00edn-Hern\u00e1ndez","year":"2009","journal-title":"Mini Rev Med Chem"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-016-2461-3","article-title":"Hypoxia in tissue repair and fibrosis","volume":"365","author":"Darby","year":"2016","journal-title":"Cell Tissue Res"},{"key":"B37","article-title":"Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha\u2013> hypoxia response element\u2013> VEGF cascade differentially regulates vascular response and growth rate in tumors","volume":"60","author":"Tsuzuki","year":"2000","journal-title":"Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201696150","article-title":"Endothelial cell metabolism in health and disease: impact of hypoxia","volume":"36","author":"Wong","year":"2017","journal-title":"EMBO J"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.107451","article-title":"Lactate\/GPR81 signaling and proton motive force in cancer: role in angiogenesis, immune escape, nutrition, and warburg phenomenon","volume":"206","author":"Brown","year":"2020","journal-title":"Pharmacol Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0709747104","article-title":"Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis","volume":"104","author":"DeBerardinis","year":"2007","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033418","article-title":"Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis","volume":"7","author":"Sonveaux","year":"2012","journal-title":"PloS One"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-10-2828","article-title":"Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-\u03baB\/IL-8 pathway that drives tumor angiogenesis","volume":"71","author":"V\u00e9gran","year":"2011","journal-title":"Cancer Res"},{"key":"B43","article-title":"Unraveling the molecular mechanisms between inflammation and tumor angiogenesis","volume":"11","author":"Zhou","year":"2021","journal-title":"Am J Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3390\/jcm9010084","article-title":"Tumor angiogenesis and anti-angiogenic strategies for cancer treatment","volume":"9","author":"Teleanu","year":"2019","journal-title":"J Clin Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/149185","article-title":"Chronic inflammation and cytokines in the tumor microenvironment","volume":"2014","author":"Landskron","year":"2014","journal-title":"J Immunol Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/iub.1358","article-title":"Cellular and molecular mechanisms of inflammation-induced angiogenesis","volume":"67","author":"Szade","year":"2015","journal-title":"IUBMB Life"},{"key":"B47","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/mc.10126","article-title":"Modulation of the angiogenesis response through ha-ras control, placenta growth factor, and angiopoietin expression in mouse skin carcinogenesis","volume":"37","author":"Larcher","year":"2003","journal-title":"Mol Carcinog"},{"key":"B48","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.semcancer.2003.09.014","article-title":"Oncogenes and tumor angiogenesis: the question of vascular \u201csupply\u201d and vascular \u201cdemand\u201d","volume":"14","author":"Rak","year":"2004","journal-title":"Semin Cancer Biol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.3.861","article-title":"Oncogenic h-ras stimulates tumor angiogenesis by two distinct pathways","volume":"94","author":"Arbiser","year":"1997","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B50","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/micc.12119","article-title":"Shear stress regulated gene expression and angiogenesis in vascular endothelium","volume":"21","author":"Wragg","year":"2014","journal-title":"Microcirculation"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1161\/01.Res.0000101744.47866.D5","article-title":"Heparan sulfate proteoglycan is a mechanosensor on endothelial cells","volume":"93","author":"Florian","year":"2003","journal-title":"Circ Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.21.2035","article-title":"Hemodynamic shear stress and its role in atherosclerosis","volume":"282","author":"Malek","year":"1999","journal-title":"Jama"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00065.2004","article-title":"Endothelial NOS is main mediator for shear stress-dependent angiogenesis in skeletal muscle after prazosin administration","volume":"287","author":"Baum","year":"2004","journal-title":"Am J Physiology: Heart Circulatory Physiol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s004410051121","article-title":"Internal division of capillaries in rat skeletal muscle in response to chronic vasodilator treatment with alpha1-antagonist prazosin","volume":"293","author":"Zhou","year":"1998","journal-title":"Cell Tissue Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3627","article-title":"VEGF targets the tumour cell","volume":"13","author":"Goel","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15000","article-title":"Effects of vascular endothelial growth factors and their receptors on megakaryocytes and platelets and related diseases","volume":"180","author":"Yang","year":"2018","journal-title":"Br J Haematol"},{"key":"B57","article-title":"Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis","volume":"59","author":"Melincovici","year":"2018","journal-title":"Romanian J Morphology Embryology"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.2217\/fca-2016-0006","article-title":"Therapeutic angiogenesis: angiogenic growth factors for ischemic heart disease","volume":"12","author":"Henning","year":"2016","journal-title":"Future Cardiol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2018.02.011","article-title":"Angiogenesis in peripheral arterial disease","volume":"39","author":"Inampudi","year":"2018","journal-title":"Curr Opin Pharmacol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mvr.2017.12.002","article-title":"Important signals regulating coronary artery angiogenesis","volume":"117","author":"Shoeibi","year":"2018","journal-title":"Microvasc Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4708076","article-title":"The role of PDGFs and PDGFRs in colorectal cancer","volume":"2017","author":"Manzat Saplacan","year":"2017","journal-title":"Mediators Inflammation"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/164_2016_80","article-title":"Platelet-derived growth factor in heart failure","volume":"243","author":"Medamana","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.mam.2017.09.005","article-title":"Platelet-derived growth factor-c and -d in the cardiovascular system and diseases","volume":"62","author":"Lee","year":"2018","journal-title":"Mol Aspects Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-016-0502-0","article-title":"Angiopoietin-1 and angiopoietin-2 in metabolic disorders: therapeutic strategies to restore the highs and lows of angiogenesis in diabetes","volume":"39","author":"Isidori","year":"2016","journal-title":"J Endocrinol Invest"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-3995-3","article-title":"Angiopoietins and diabetic nephropathy","volume":"59","author":"Gnudi","year":"2016","journal-title":"Diabetologia"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2016.278","article-title":"Therapeutic targeting of the angiopoietin-TIE pathway","volume":"16","author":"Saharinen","year":"2017","journal-title":"Nat Rev Drug Discovery"},{"key":"B67","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1096\/fj.201800640RR","article-title":"Pro- and antiangiogenic therapies: current status and clinical implications","volume":"33","author":"Rust","year":"2019","journal-title":"FASEB J"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-15-0255","article-title":"Classifying cancers based on T-cell infiltration and PD-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.ccell.2017.10.003","article-title":"An HIF-1\u03b1\/VEGF-A axis in cytotoxic T cells regulates tumor progression","volume":"32","author":"Palazon","year":"2017","journal-title":"Cancer Cell"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20140559","article-title":"VEGF-a modulates expression of inhibitory checkpoints on CD8+ T cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J Exp Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/nm1096-1096","article-title":"Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells","volume":"2","author":"Gabrilovich","year":"1996","journal-title":"Nat Med"},{"key":"B72","article-title":"Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages","volume":"92","author":"Gabrilovich","year":"1998","journal-title":"vivo. Blood"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/nature10169","article-title":"Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and t(reg) cells","volume":"475","author":"Facciabene","year":"2011","journal-title":"Nature"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1111\/febs.13656","article-title":"Targeting regulatory T cells in tumors","volume":"283","author":"Liu","year":"2016","journal-title":"FEBS J"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-09-4672","article-title":"Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes","volume":"70","author":"Movahedi","year":"2010","journal-title":"Cancer Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118163","article-title":"Anti-angiogenesis: opening a new window for immunotherapy","volume":"258","author":"Guo","year":"2020","journal-title":"Life Sci"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aak9670","article-title":"Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade","volume":"9","author":"Schmittnaegel","year":"2017","journal-title":"Sci Transl Med"},{"key":"B78","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-018-0644-y","article-title":"Targeting the IDO1 pathway in cancer: from bench to bedside","volume":"11","author":"Liu","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/nm0901-987","article-title":"Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy","volume":"7","author":"Jain","year":"2001","journal-title":"Nat Med"},{"key":"B80","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ejpb.2020.03.003","article-title":"Improving tumor hypoxia and radiotherapy resistance via in situ nitric oxide release strategy","volume":"150","author":"Tu","year":"2020","journal-title":"Eur J Pharmaceutics Biopharmaceutics"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2021.108540","article-title":"Retinal hypoxia and angiogenesis with methamphetamine","volume":"206","author":"Lee","year":"2021","journal-title":"Exp Eye Res"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.18383\/j.tom.2020.00046","article-title":"Correlation of tumor hypoxia metrics derived from (18)F-fluoromisonidazole positron emission tomography and pimonidazole fluorescence images of optically cleared brain tissue","volume":"6","author":"Scarpelli","year":"2020","journal-title":"Tomography"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2017.05.016","article-title":"Enhanced tumor therapy via drug co-delivery and in situ vascular-promoting strategy","volume":"258","author":"Yin","year":"2017","journal-title":"J Control Release"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-019-0570-3","article-title":"Delivery of nitric oxide with a nanocarrier promotes tumour vessel normalization and potentiates anti-cancer therapies","volume":"14","author":"Sung","year":"2019","journal-title":"Nat Nanotechnol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.9b08460","article-title":"Gold nanoparticles induce tumor vessel normalization and impair metastasis by inhibiting endothelial Smad2\/3 signaling","volume":"14","author":"Huang","year":"2020","journal-title":"ACS Nano"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03701-8","article-title":"Targeting tumor vascularization: promising strategies for vascular normalization","volume":"147","author":"Zheng","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s13046-020-01762-0","article-title":"Amino acid transporter LAT1 in tumor-associated vascular endothelium promotes angiogenesis by regulating cell proliferation and VEGF-a-dependent mTORC1 activation","volume":"39","author":"Quan","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1007\/s12079-016-0352-8","article-title":"VEGF-A\/VEGFR2 signaling network in endothelial cells relevant to angiogenesis","volume":"10","author":"Abhinand","year":"2016","journal-title":"J Cell Commun Signal"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.188219","article-title":"VEGF induces signalling and angiogenesis by directing VEGFR2 internalisation through macropinocytosis","volume":"129","author":"Basagiannis","year":"2016","journal-title":"J Cell Sci"},{"key":"B90","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1080\/13543776.2021.1935872","article-title":"An updated patent review of VEGFR-2 inhibitors (2017-present)","volume":"31","author":"Farghaly","year":"2021","journal-title":"Expert Opin Ther Pat"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgi024","article-title":"Combined inhibition of PDGF and VEGF receptors by ellagic acid, a dietary-derived phenolic compound","volume":"26","author":"Labrecque","year":"2005","journal-title":"Carcinogenesis"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3390\/ijms140815885","article-title":"Angiogenesis-related pathways in the pathogenesis of ovarian cancer","volume":"14","author":"Gavalas","year":"2013","journal-title":"Int J Mol Sci"},{"key":"B93","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3892\/or.2020.7580","article-title":"HDGF enhances VEGF\u2212dependent angiogenesis and FGF\u22122 is a VEGF\u2212independent angiogenic factor in non\u2212small cell lung cancer","volume":"44","author":"Eguchi","year":"2020","journal-title":"Oncol Rep"},{"key":"B94","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3390\/cells8050471","article-title":"Role of angiopoietin-2 in vascular physiology and pathophysiology","volume":"8","author":"Akwii","year":"2019","journal-title":"Cells"},{"key":"B95","doi-asserted-by":"publisher","first-page":"12035","DOI":"10.3390\/ijms222112035","article-title":"Angiogenesis in chronic inflammatory skin disorders","volume":"22","author":"Lee","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0078-x","article-title":"Differential expression of IL-6\/IL-6R and MAO-a regulates invasion\/angiogenesis in breast cancer","volume":"118","author":"Bharti","year":"2018","journal-title":"Br J Cancer"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcb.2010.10.007","article-title":"The soluble interleukin 6 receptor: generation and role in inflammation and cancer","volume":"90","author":"Chalaris","year":"2011","journal-title":"Eur J Cell Biol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2014.00114","article-title":"The role IL-1 in tumor-mediated angiogenesis","volume":"5","author":"Voronov","year":"2014","journal-title":"Front Physiol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2020.155066","article-title":"Importance of TNF-alpha and its alterations in the development of cancers","volume":"130","author":"Mahdavi Sharif","year":"2020","journal-title":"Cytokine"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2020.08.002","article-title":"The role of HIF in immunity and inflammation","volume":"32","author":"McGettrick","year":"2020","journal-title":"Cell Metab"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1002\/biof.1702","article-title":"The HIF-1\/SNHG1\/miR-199a-3p\/TFAM axis explains tumor angiogenesis and metastasis under hypoxic conditions in breast cancer","volume":"47","author":"Zuo","year":"2021","journal-title":"Biofactors"},{"key":"B102","doi-asserted-by":"publisher","first-page":"5413","DOI":"10.1111\/febs.16110","article-title":"Regulation of redox signaling in HIF-1-dependent tumor angiogenesis","volume":"289","author":"Manuelli","year":"2021","journal-title":"FEBS J"},{"key":"B103","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3390\/biomedicines6020044","article-title":"Subunit-specific role of NF-\u03baB in cancer","volume":"6","author":"Kaltschmidt","year":"2018","journal-title":"Biomedicines"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009428","article-title":"IKKalpha and IKKbeta each function to regulate NF-kappaB activation in the TNF-induced\/canonical pathway","volume":"5","author":"Adli","year":"2010","journal-title":"PloS One"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.07.003","article-title":"A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis","volume":"30","author":"Kollmann","year":"2016","journal-title":"Cancer Cell"},{"key":"B106","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.vph.2015.05.008","article-title":"The critical role of akt in cardiovascular function","volume":"74","author":"Abeyrathna","year":"2015","journal-title":"Vascul Pharmacol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1242\/dev.137919","article-title":"Vegfa signals through ERK to promote angiogenesis, but not artery differentiation","volume":"143","author":"Shin","year":"2016","journal-title":"Development"},{"key":"B108","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12933-015-0180-9","article-title":"Inhibition of protein kinase c enhances angiogenesis induced by platelet-derived growth factor c in hyperglycemic endothelial cells","volume":"14","author":"Moriya","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/37040","article-title":"Protein kinase CK2 and angiogenesis","volume":"23","author":"Montenarh","year":"2014","journal-title":"Adv Clin Exp Med"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01278","article-title":"Mechanisms of action of novel drugs targeting angiogenesis-promoting matrix metalloproteinases","volume":"10","author":"Fields","year":"2019","journal-title":"Front Immunol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3437","article-title":"Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs","volume":"6","author":"Ben-Batalla","year":"2015","journal-title":"Oncotarget"},{"key":"B112","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/cvr\/cvs143","article-title":"Emerging role of PKA\/eNOS pathway in therapeutic angiogenesis for ischaemic tissue diseases","volume":"95","author":"Bir","year":"2012","journal-title":"Cardiovasc Res"},{"key":"B113","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3322\/caac.21596","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-021-00833-8","article-title":"A review of cancer immunotherapy toxicity: immune checkpoint inhibitors","volume":"17","author":"Chhabra","year":"2021","journal-title":"J Med Toxicol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.7150\/thno.65828","article-title":"Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells","volume":"12","author":"Tu","year":"2022","journal-title":"Theranostics"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01201-z","article-title":"Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts","volume":"124","author":"Kato","year":"2021","journal-title":"Br J Cancer"},{"key":"B117","doi-asserted-by":"publisher","first-page":"TPS9112","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS9112","article-title":"Phase I\/II study of nivolumab and ipilimumab combined with nintedanib in advanced NSCLC","volume":"36","author":"Puri","year":"2018","journal-title":"J Clin Oncol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12624","article-title":"Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma","volume":"7","author":"Wallin","year":"2016","journal-title":"Nat Commun"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.730240","article-title":"Multi-omics analysis of the anti-tumor synergistic mechanism and potential application of immune checkpoint blockade combined with lenvatinib","volume":"9","author":"Lu","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212513","article-title":"Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway","volume":"14","author":"Kato","year":"2019","journal-title":"PloS One"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.02627","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer","volume":"38","author":"Makker","year":"2020","journal-title":"J Clin Oncol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.00808","article-title":"Phase ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2018.1543526","article-title":"Beneficial effects of sunitinib on tumor microenvironment and immunotherapy targeting death receptor5","volume":"8","author":"Tsukita","year":"2019","journal-title":"Oncoimmunology"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202001596","article-title":"The beneficial role of sunitinib in tumor immune surveillance by regulating tumor PD-L1","volume":"8","author":"Li","year":"2021","journal-title":"Adv Sci (Weinh)"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2011.01.030","article-title":"MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy","volume":"11","author":"Finke","year":"2011","journal-title":"Int Immunopharmacol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001561","article-title":"Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib\/II trial","volume":"8","author":"Martin-Broto","year":"2020","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1198972\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T08:03:30Z","timestamp":1685693010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1198972\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,2]]},"references-count":128,"alternative-id":["10.3389\/fimmu.2023.1198972"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1198972","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,2]]},"article-number":"1198972"}}